|
Market Closed –
|
|
|||
|
39.99 USD |
+5.40% |
41.46 |
+3.68% | |
Published on 05/21/2025 at 08:56
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment |
09:03am |
MT |
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy |
08:56am |
RE |
|
The Fragile Confidence Act |
May. 20 |
 |
|
Analyst recommendations; Applovin, HP, Metlife, Micron, Pure Storage…. |
May. 20 |
|
|
Sarepta Therapeutics, Inc. Presents Data At the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 |
May. 16 |
CI |
|
Sarepta Therapeutics, Inc. Shares New Protein Expression and Safety Results from Endeavor in Participants 2 Years Old At Time of Treatment |
May. 16 |
CI |
|
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy |
May. 16 |
MT |
|
When the Numbers Don’t Add Up |
May. 15 |
|
|
Analyst recommendations: Nvidia, On Holding, Duolingo, Target, UnitedHealth… |
May. 15 |
|
|
Sarepta Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:40 AM |
May. 14 |
|
|
Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan |
May. 13 |
MT |
|
Sarepta Therapeutics, Inc. Announces Approval in Japan of ELEVIDYS, A Gene Therapy to Treat Duchenne Muscular Dystrophy |
May. 13 |
CI |
|
Eighty Percent and Falling |
May. 09 |
|
|
Analyst recommendations: Airbnb, AMD, Fortinet, Uber, Estee Lauder… |
May. 09 |
|
|
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating |
May. 08 |
MT |
|
About Doves and Deals |
May. 07 |
|
|
Analyst recommendations: Skechers, Doordash, Stellantis, The Trade Desk, Yeti Holdings… |
May. 07 |
|
|
Sarepta Therapeutics Swings to Non-GAAP Q1 Loss; Shares Tumble After Hours |
May. 06 |
MT |
|
Sarepta Therapeutics, Inc., Q1 2025 Earnings Call, May 06, 2025 |
May. 06 |
|
|
Earnings Flash (SRPT) Sarepta Therapeutics Reports Q1 Revenue $744.9M, vs. FactSet Est of $687.5M |
May. 06 |
MT |
|
Earnings Flash (SRPT) Sarepta Therapeutics Posts Q1 Loss $-3.42 Per Share |
May. 06 |
MT |
|
Sarepta Therapeutics, Inc. Revises Earnings Guidance for 2025 |
May. 06 |
CI |
|
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 06 |
CI |
|
US FDA names oncologist Vinay Prasad as top vaccine official |
May. 06 |
RE |
|
Sarepta Therapeutics To Announce First Quarter 2025 Financial Results |
Apr. 22 |
RE |
SRPT: Dynamic Chart
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Buy
Average target price
89.96USD
Spread / Average Target
+124.95%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
